Elizabeth Cairns is a Senior Biopharma Journalist at Informa. She specializes in covering themes related to medicine and healthcare, pharmaceuticals, and public health, with a focus on topics such as drugs and medication, pharmaceutical regulation, and patient care. Elizabeth's work has been featured in notable publications including Citeline and Endpoints News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Elizabeth Cairns' coverage primarily focuses on the healthcare and pharmaceutical industry, with a strong emphasis on biopharmaceuticals, clinical trials, drug development, and medical research. She frequently cites data and press releases in her articles.
If you are looking to reach out to Elizabeth Cairns for potential coverage or collaboration opportunities, consider offering access to exclusive data or insights related to breakthroughs in drug development or clinical trial results. Given her focus on scientific themes as well as private sector announcements, she might be interested in pitches that provide unique perspectives from key figures within pharmaceutical companies regarding new developments and trends shaping the industry.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Zymeworks CEO Kenneth Galbraith makes the case for the $929M Theravance deal, arguing the net outlay is only about $120M.
By: Elizabeth Cairns
Abivax says new Phase 3 data show cancer rates within expected range for its UC drug obefazimod, though Jefferies flags lingering FDA risk.
By: Elizabeth Cairns
Senior biopharma journalist Armed with impressive Phase 3 data, BrightGene is taking its obesity shot to Chinese regulators. It expects trial data in the West to be even …
By: Elizabeth Cairns
Roche's Genentech deepens its oncology pipeline bets by paying Astex $25M upfront (up to $490M+ milestones) for early breast cancer compounds.
By: Elizabeth Cairns
Hengrui/Kailera's GLP-1 pill HRS-7535 met obesity & diabetes China trial endpoints but showed high nausea & vomiting, raising concerns vs Lilly & Novo pills.
By: Elizabeth Cairns
Sino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday.
By: Elizabeth Cairns
Biohaven's Phase 2 trial of its muscle-building product taldefgrobep alfa will read out later this year, with Eli Lilly’s similar muscle-boosting drug in its sights.
AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.
By: Elizabeth Cairns
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
We value your privacy We use cookies to enhance your browsing experience and analyze our traffic. By selecting “Accept All”, you consent to our use of cookies.
